BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen YY, Lu YC, Shen DP, Liu YJ, Su XY, Zhu GS, Yin XL, Ni XZ. Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients. World J Gastroenterol 2013; 19(28): 4568-4575 [PMID: 23901234 DOI: 10.3748/wjg.v19.i28.4568] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Kim JH, Jeong SY, Jang HJ, Park ST, Kim HS. FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:762528. [PMID: 34737965 DOI: 10.3389/fonc.2021.762528] [Reference Citation Analysis]
2 Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148 [PMID: 30949443 DOI: 10.5306/wjco.v10.i3.136] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, Gray NS. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A 2014;111:E4869-77. [PMID: 25349422 DOI: 10.1073/pnas.1403438111] [Cited by in Crossref: 112] [Cited by in F6Publishing: 94] [Article Influence: 14.0] [Reference Citation Analysis]
4 Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015; 21(41): 11621-11635 [PMID: 26556991 DOI: 10.3748/wjg.v21.i41.11621] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
5 Wang P, Wang Y, Hang B, Zou X, Mao JH. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget 2016;7:55343-51. [PMID: 27419373 DOI: 10.18632/oncotarget.10533] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 21.8] [Reference Citation Analysis]
6 Moazeni-Roodi A, Sarabandi S, Karami S, Hashemi M, Ghavami S. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer. Biosci Rep 2020;40:BSR20192051. [PMID: 33017009 DOI: 10.1042/BSR20192051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Peng T, Sun Y, Lv Z, Zhang Z, Su Q, Wu H, Zhang W, Yuan W, Zuo L, Shi L, Zhang LF, Zhou X, Mi Y. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer. Sci Rep 2021;11:1373. [PMID: 33446698 DOI: 10.1038/s41598-020-80146-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen L, Lei Z, Ma X, Huang Q, Zhang X, Zhang Y, Hao P, Yang M, Zhao X, Chen J, Liu G, Zheng T. Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population. Sci Rep 2016;6:33604. [PMID: 27640814 DOI: 10.1038/srep33604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Xiong SW, Ma J, Feng F, Fu W, Shu SR, Ma T, Wu C, Liu GC, Zhu J. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. Oncotarget 2017;8:25300-9. [PMID: 28445975 DOI: 10.18632/oncotarget.15811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Hong CS, Sun EG, Choi JN, Kim DH, Kim JH, Ryu KH, Shim HJ, Hwang JE, Bae WK, Kim HR, Kim KK, Jung C, Chung IJ, Cho SH. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. Cancer Sci 2020;111:3268-78. [PMID: 32533590 DOI: 10.1111/cas.14526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cho SH, Hong CS, Kim HN, Shin MH, Kim KR, Shim HJ, Hwang JE, Bae WK, Chung IJ. FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition. Cancer Res Treat 2017;49:766-77. [PMID: 27857023 DOI: 10.4143/crt.2016.457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
12 Sheu MJ, Hsieh MJ, Chiang WL, Yang SF, Lee HL, Lee LM, Yeh CB. Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS One 2015;10:e0122961. [PMID: 25860955 DOI: 10.1371/journal.pone.0122961] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]